Moderna made the mRNA COVID vaccine, developing cancer and flu shots.
Moderna, Inc. (MRNA) is expected to report earnings on Thursday, November 5, 2026, after the close. Estimated release time 07:01 ET. Consensus EPS estimate is $-1.37.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-07-31 | FY2026 Q2 | $-2.03 | $-1.97 | +3.0% | $145.00M |
| 2026-05-01 | FY2026 Q1 | $-4.45 | $-3.40 | +23.6% | $389.00M |
| 2026-02-13 | FY2025 Q4 | $-2.54 | $-2.11 | +16.9% | $678.00M |
| 2025-05-01 | FY2025 Q1 | $-2.92 | $-2.52 | +13.7% | $107.00M |
| 2025-02-14 | FY2024 Q4 | $-2.68 | $-2.50 | +6.7% | $956.00M |
| 2024-11-07 | FY2024 Q3 | $-1.91 | $0.03 | +101.6% | $1.85B |
| 2024-08-01 | FY2024 Q2 | $-3.35 | $-3.33 | +0.6% | $241.00M |
| 2024-05-02 | FY2024 Q1 | $-3.56 | $-3.07 | +13.8% | $167.00M |
MRNA has beaten consensus EPS in 8 of its last 8 reported quarters.
Highlights from MRNA's Jul 31 report: EPS of -$1.97 — a beat vs the -$2.03 estimate (+3%); revenue of $145M — a big beat vs the $103M consensus (+41%). Focus now shifts to respiratory vaccine outlook and cash runway.
See MRNA on the live calendar →